Literature DB >> 30637723

Critical limb ischemia: Current and novel therapeutic strategies.

Mohammadhossein Hassanshahi1, Samira Khabbazi1, Yaser Peymanfar1, Alireza Hassanshahi2, Zahra Hosseini-Khah3, Yu-Wen Su1, Cory J Xian1.   

Abstract

Critical limb ischemia (CLI) is the advanced stage of peripheral artery disease spectrum and is defined by limb pain or impending limb loss because of compromised blood flow to the affected extremity. Current conventional therapies for CLI include amputation, bypass surgery, endovascular therapy, and pharmacological approaches. Although these conventional therapeutic strategies still remain as the mainstay of treatments for CLI, novel and promising therapeutic approaches such as proangiogenic gene/protein therapies and stem cell-based therapies have emerged to overcome, at least partially, the limitations and disadvantages of current conventional therapeutic approaches. Such novel CLI treatment options may become even more effective when other complementary approaches such as utilizing proper bioscaffolds are used to increase the survival and engraftment of delivered genes and stem cells. Therefore, herein, we address the benefits and disadvantages of current therapeutic strategies for CLI treatment and summarize the novel and promising therapeutic approaches for CLI treatment. Our analyses also suggest that these novel CLI therapeutic strategies show considerable advantages to be used when current conventional methods have failed for CLI treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiogenesis; bio-scaffolds; critical limb ischemia; stem cell therapy

Year:  2019        PMID: 30637723     DOI: 10.1002/jcp.28141

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Molecular basis of the effect of atorvastatin pretreatment on stem cell therapy in chronic ischemic diseases - critical limb ischemia.

Authors:  A Adamičková; A Gažová; M Adamička; N Chomaničová; S Valašková; Z Červenák; B Šalingová; J Kyselovič
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

2.  Oxygen-release microspheres capable of releasing oxygen in response to environmental oxygen level to improve stem cell survival and tissue regeneration in ischemic hindlimbs.

Authors:  Ya Guan; Ning Gao; Hong Niu; Yu Dang; Jianjun Guan
Journal:  J Control Release       Date:  2021-01-27       Impact factor: 9.776

3.  A Swine Hind Limb Ischemia Model Useful for Testing Peripheral Artery Disease Therapeutics.

Authors:  Juline N Deppen; Sydney C Ginn; Na Hee Kim; Lanfang Wang; Ronald J Voll; Steven H Liang; Mark M Goodman; John N Oshinski; Rebecca D Levit
Journal:  J Cardiovasc Transl Res       Date:  2021-05-28       Impact factor: 4.132

Review 4.  Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy.

Authors:  Pawan Faris; Sharon Negri; Angelica Perna; Vittorio Rosti; Germano Guerra; Francesco Moccia
Journal:  Int J Mol Sci       Date:  2020-10-07       Impact factor: 5.923

Review 5.  Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.

Authors:  Zeinab Shirbaghaee; Mohammad Hassani; Saeed Heidari Keshel; Masoud Soleimani
Journal:  Stem Cell Res Ther       Date:  2022-09-06       Impact factor: 8.079

Review 6.  Macrophage-Mediated Inflammation in Skin Wound Healing.

Authors:  Alireza Hassanshahi; Mohammad Moradzad; Saman Ghalamkari; Moosa Fadaei; Allison J Cowin; Mohammadhossein Hassanshahi
Journal:  Cells       Date:  2022-09-21       Impact factor: 7.666

7.  Three-year outcomes of peripheral blood mononuclear cells vs purified CD34+ cells in the treatment of angiitis-induced no-option critical limb ischemia and a cost-effectiveness assessment: A randomized single-blinded noninferiority trial.

Authors:  Hao Liu; Tianyue Pan; Yuan Fang; Gang Fang; Yifan Liu; Xiaolang Jiang; Bin Chen; Zheng Wei; Shiyang Gu; Peng Liu; Weiguo Fu; Zhihui Dong
Journal:  Stem Cells Transl Med       Date:  2021-01-05       Impact factor: 6.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.